The groundbreaking evolution of tumor immunotherapy has unveiled novel immune checkpoint molecules, such as TIM3, LAG-3, and TIGIT, heralding new possibilities for cancer immunotherapy. The gene discussed is HAVCR2; the disease is neoplasm.